院外心脏骤停后治疗性低温持续时间:ICECAP随机临床试验
ICECAP为美国71家医院开展的多中心、随机、适应性分配临床试验,纳入院外心脏骤停后仍昏迷、4小时内达到<34℃且已启动专用温控设备的成人患者,2020年6月至2025年6月共随机1158例(不可电击心律883例,可电击心律275例)。主要终点为90天加权改良Rankin量表评分,采用贝叶斯时长-反应模型分析。结果显示不可电击心律队列中6小时为达到最大平均加权mRS评分的最短时长的后验概率为0.51,可电击心律队列结果相似;各降温时长间次要终点及死亡率无差异。
要点
- 纳入标准:院外心脏骤停后仍昏迷、4小时内达到目标温度<34℃且已启动专用温控设备的成人患者。
- 不可电击心律队列中,6小时为达到最大平均加权mRS评分的最短时长的后验概率为0.51。
- 可电击心律队列结果与不可电击心律队列相似。
- 各降温时长间次要终点及死亡率无差异。
- 延长33℃低温治疗持续时间未改善90天神经功能。
适用人群与场景
- 纳入:院外心脏骤停后仍昏迷的成人患者,且在心脏骤停后4小时内达到目标温度<34℃并已启动专用温控设备。
- 场景:美国71家医院,2020年6月至2025年6月入组。
- 排除:原文未提及。
诊断标准与关键阈值
- 低温方案:治疗性低温目标温度33℃。
- 主要终点:90天神经功能,采用加权改良Rankin量表评分,贝叶斯时长-反应模型分析。
- 最优时长定义:在任何时长中观察到最佳结局一致的最短时长。
处置流程与药物剂量
- 第一步:院外心脏骤停后仍昏迷的成人,启动专用温控设备,4小时内达到目标温度<34℃。
- 第二步:目标温度33℃治疗性低温,适应性随机分配至6、12、18、24、30、36、42、48、60或72小时。
- 第三步:前200例按1:1:1随机分配至12、24、48小时;后续采用反应适应性随机算法,按心律类型分别优先分配至最可能最优且最能提供时长-反应曲线信息的组。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心、随机、适应性分配临床试验,美国71家医院,共随机1158例(不可电击心律883例,可电击心律275例)。
- 人群特征:中位年龄61岁(IQR 50-70),女性39.6%。
- 主要终点:不可电击心律队列中,6小时为达到最大平均加权mRS评分的最短时长的后验概率为0.51;可电击心律队列结果相似。
- 次要终点与不良事件:各降温时长间次要终点及死亡率无差异。
- 试验因中期分析达到预设停止规则而终止。
证据类型、等级与局限
- 证据类型:多中心随机适应性分配临床试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未提及;设计本身为适应性分配、贝叶斯分析,主要终点为模型估计的后验概率。
对床旁实践的改变
- 对于院外心脏骤停后昏迷、4小时内达到<34℃并已启动专用温控设备的成人,延长33℃低温持续时间未改善90天神经功能,不支持以延长降温时长来追求神经保护获益。
- 不可电击心律患者中6小时为最短有效时长的后验概率仅0.51,不能据此将6小时作为确定的最优时长推荐。
- 各降温时长间死亡率无差异,时长选择不影响生存率。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Therapeutic hypothermia is widely used for neuroprotection following cardiac arrest, but clinical trials have not consistently demonstrated improved neurological outcomes, and the optimal duration of cooling remains uncertain.
OBJECTIVE: To determine the duration of therapeutic hypothermia that maximizes neurological recovery in comatose survivors of out-of-hospital cardiac arrest.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, adaptive-allocation clinical trial conducted at 71 hospitals in the US. Adults with out-of-hospital cardiac arrest who remained unconscious, achieved a target temperature less than 34 °C within 4 hours of cardiac arrest, and had a definitive temperature control device started were eligible. Patients were enrolled between June 2020 and June 2025.
INTERVENTIONS: Therapeutic hypothermia at 33 °C with adaptive randomized allocation to cooling durations of 6, 12, 18, 24, 30, 36, 42, 48, 60, and 72 hours. The first 200 patients were randomized to 12-, 24-, and 48-hour durations in a 1:1:1 ratio. Subsequently, a response-adaptive randomization algorithm allocated preferentially to the groups most likely to be optimal and to best inform the duration-response curve separately within each rhythm type.
MAIN OUTCOMES AND MEASURES: The primary outcome was neurological function at 90 days, measured using a weighted modified Rankin Scale score, analyzed using a bayesian duration-response model. The primary analysis estimated the posterior probability that each duration was optimal, wherein optimal indicates the shortest duration consistent with the best outcome observed at any duration.
RESULTS: A total of 1158 patients were randomized (883 with nonshockable rhythms and 275 with shockable rhythms). Participants had a median age of 61 (IQR, 50-70) years and 39.6% were female. The trial met a prespecified stopping rule at the interim analysis. For the nonshockable rhythm cohort, the posterior probability that 6 hours was the shortest duration achieving the maximal mean weighted modified Rankin Scale score was 0.51. Results were similar in the shockable rhythm cohort. No differences were observed in secondary outcomes or mortality across cooling durations.
CONCLUSIONS AND RELEVANCE: Among comatose survivors of out-of-hospital cardiac arrest treated with therapeutic hypothermia at 33 °C, increasing cooling duration did not improve neurological outcomes.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04217551.
参考来源
- Meurer WJ, Yeatts SD, Geocadin RG, et al. Duration of Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: The ICECAP Randomized Clinical Trial. JAMA. 2026. PMID: 42554995. doi:10.1001/jama.2026.10247
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。